Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT02572050

Assessment of a Robotic Distal Gastrectomy on Non-inferiority of N2 Area Nodal Dissection

Conditions: Gastric Cancer

Sex: All
Ages: 19 Years – N/A
Healthy volunteers: No
Phase: PHASE2
Enrollment: 87
Sponsor: National Cancer Center, Korea

Location: National Cancer Center of Korea Goyang-si Gyeonggi-do

Summary

Designed as a single arm multi-center prospective phase II trial, which evaluates the number of dissected lymph nodes in the N2-area as a surrogate parameter for adequate D2 lymphadenectomy in robotic distal gastrectomy (RDG) for clinical stage II or III gastric cancer.

Eligibility Criteria

Inclusion Criteria: * Histologically proven adenocarcinoma of the stomach in patients that have not received any previous treatment for their cancer * Tumours should be stage II or III according to the UICC 7th edition with no sign of distant metastasis and deemed resectable (R0) by the operating surgeon on preoperative staging by EGD, and CT of abdomen and pelvis * Location of the tumor at the pylorus, antrum, angle, lower body and midbody to allow subtotal gastrectomy * Age ≥ 19 years * Written informed consent Exclusion Criteria: * Performance status ≥3 * Patients not eligible for surgery (ASA \>=4) * History of another primary cancer, except curatively treated in situ cervical cancer, curatively resected non-melanoma skin cancer. The inclusion of patients with other types of cancer that were successfully treated and did not recur within the last 5 years prior to study enrolment have to be discussed with the principal investigator. * Evidence of distant metastasis on clinical staging * Primary tumour deemed unresectable by operating surgeon * Inadequate organ function as below * Bone marrow function defined as: (ANC ≤1.0x109/l, WBC (total) ≤ 2.5x109/l, Platelet Count ≤ 70x109/l, Haemoglobin ≤ 8 g/dl (can be post-transfusion) * Renal function with serum Creatinine ≥1.5 mg/dL) ③ Liver function defined as (Total Bilirubin≥ 2.0x (ULN), ALT/AST ≥2.5x ULN) ④ Coagulation profile: with PT (INR) ≥1.5, aPTT(sec) ≥1.5xULN * Women of childbearing potential should have a negative pregnancy test within 7 days prior to commencing treatment, and must take adequate contraceptive precautions * Simultaneous participation in another clinical trial.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT02572050). StuddyBuddy aggregates publicly available trial information.